NIH Proposes Sweeping Biosafety Overhaul as White House Dual-Use Policy Leaves Synthesis Screening Gap

The National Institutes of Health published a draft biosafety policy on August 19 that, if finalized, would retire the foundational Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules and replace them with a broader, risk-based framework covering hazardous biological research that the old rules never reached. Public comments are due to NIH's Office of Science Policy by October 19.

According to a notice posted on the NIH Grants page and separately published in the Federal Register on September 14, the draft policy would expand institutional biosafety committee authority beyond genetically modified organisms to cover wild-type pathogens, toxins, and prions. It would also compress the incident-reporting window and formalize Biosafety Officer duties, including active verification of containment practices. Global Biodefense's September 2 digest reported the 24-hour reporting requirement specifically, a sharp tightening from the current 30-day window.

The NIH framing is modernization, and there's a reasonable case for that. The existing guidelines date to the mid-1970s, when synthetic biology, agentic AI platforms, and the current scale of distributed biotech did not exist. NIH's own notice acknowledges that current life sciences research "extends well beyond recombinant DNA technologies" and that emerging biotechnologies require a framework capable of addressing a broader risk spectrum, according to a summary reviewed by Safety Partners LLC. That's a factual description of the problem, not a debatable one.

But the draft doesn't land in a clean regulatory environment. It arrives roughly two months after the White House Office of Science and Technology Policy approved, on July 20, the United States Government Policy for Stopping High-Risk Life Sciences Research, pursuant to Executive Order 14292, "Improving the Safety and Security of Biological Research." According to ASPR's policy page, that July document replaces the 2024 DURC and Pathogens with Enhanced Pandemic Potential oversight policy and prohibits federal funding for life sciences research that poses the highest societal risks without commensurate benefits.

The July policy also bans federal support for dangerous gain-of-function research and introduces enhanced review requirements for projects that may increase the harmful consequences of biological agents, according to NIH's Office of Science Policy. So there are now two major federal biosafety documents in active circulation, one finalized in July, one in draft as of August, and they don't obviously resolve into a unified framework. Institutions with ongoing high-risk research portfolios are navigating both simultaneously.

The more pressing gap, flagged in a Congressional Research Service analysis updated in August and published on Congress.gov, is the nucleic acid synthesis screening framework. EO 14292 directed OSTP to revise or replace the 2024 Framework for Nucleic Acid Synthesis Screening, which required federally funded researchers to purchase gene synthesis only from companies following certain screening procedures. As of the CRS analysis, OSTP had not updated that framework. EO 14292's 90-, 120-, and 180-day deadlines for successor policies have all passed, according to a CASRAI implementation review.

That gap matters for dual-use risk in a concrete way. The synthesis screening rules are one of the few chokepoints in the U.S. biosecurity architecture that apply at the point of capability acquisition rather than at the point of publication or grant approval. Leaving the 2024 framework in legal limbo, while the EO technically rescinded its predecessor and OSTP has not issued a replacement, creates an ambiguous compliance environment for both researchers and synthesis providers. This is a low-to-moderate confidence assessment based on open-source policy documents; agency implementation guidance could clarify the picture.

The NIH draft biosafety policy comment period closes October 19. Whether the two documents, the July high-risk life sciences policy and the August biosafety draft, will be formally reconciled before either is fully operational remains an open question.

Sources cited:
- NIH Grants Notice NOT-OD-26-112 (https://grants.nih.gov/grants/guide/notice-files/NOT-OD-26-112.html)
- Federal Register, Draft NIH Biosafety Policy for Research Involving Biohazards, 91 FR 58132 (https://www.federalregister.gov/documents/2026/09/14/2026-18646/draft-nih-biosafety-policy-for-research-involving-biohazards)
- Global Biodefense Today, September 2, 2026 (https://globalbiodefense.com/2026/09/02/global-biodefense-today-september-2-2026/)
- ASPR, United States Government Policy for Stopping High-Risk Life Sciences Research (https://www.aspr.gov/readiness-response/medical-countermeasures-biodefense/s3/high-consequence-research-oversight/USG-Policy-For-Stopping-High-Risk-Life-Sciences-Research)
- NIH Office of Science Policy, White House Releases New U.S. Government Policy for Stopping High-Risk Life Sciences Research (https://osp.od.nih.gov/white-house-releases-new-u-s-government-policy-for-stopping-high-risk-life-sciences-research/)
- Congressional Research Service, Artificial Intelligence and Biosecurity Issues (IF13269), Congress.gov (https://www.congress.gov/crs-product/IF13269)
- CASRAI, Executive Order 14292: Gain-of-Function Pause (https://casrai.org/news/executive-order-14292-biological-research-security)
- Safety Partners LLC, NIH's Draft Biosafety Policy: What EHS Professionals Need to Know (https://safetypartnersinc.com/nihs-draft-biosafety-policy-what-ehs-professionals-need-to-know/)